China

CanSino Biologics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CHINA China

Post An Enquiry

Virtual Booth

BE PHARMA 2020

Participation Not Confirmed

Update your events

China's Cansino Kicks Off Phase III Vaccine Clinical Trials in Russia

Lead Product(s): Ad5-nCoV

Therapeutic Area: Infections and Infectious Diseases Product Name: Ad5-nCoV

Highest Development Status: Phase III Product Type: Vaccine

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable September 03, 2020

Details:

Russia has granted approval for a Phase III clinical trial of China-based CanSino Biologics’ Covid-19 vaccine candidate, developed in alliance with the Chinese military’s research arm.

Sinovac Biotech

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CHINA China

Post An Enquiry

Virtual Booth

BE PHARMA 2020

Participation Not Confirmed

Update your events

Sinovac Signs Agreement with Bio Farma Indonesia for COVID-19 Vaccine Cooperation

Lead Product(s): CoronaVac

Therapeutic Area: Infections and Infectious Diseases Product Name: CoronaVac

Highest Development Status: Phase III Product Type: Vaccine

Partner/Sponsor/Collaborator: Bio Farma

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement August 25, 2020

Details:

Sinovac is committed to supply Bio Farma bulk vaccine to enable the latter to produce at least 40 million doses of CoronaVac in Indonesia before March 2021; after March 2021, Sinovac will continue to supply the required quantity of the bulk vaccine until the end of 2021.

Sinopharm

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CHINA China

Post An Enquiry

Virtual Booth

BE PHARMA 2020

Participation Not Confirmed

Update your events

Sinopharm Shares Phase 2 Data On Inactivated Covid-19 Vaccine

Lead Product(s): Inactivated Covid-19 vaccine

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Phase III Product Type: Vaccine

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable August 13, 2020

Details:

Sinopharm's inactivated COVID-19 vaccine had a low rate of adverse reactions and demonstrated immunogenicity, but longer-term assessment of safety and efficacy will require phase 3 trials.

Sinovac Biotech

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CHINA China

Post An Enquiry

Virtual Booth

BE PHARMA 2020

Participation Not Confirmed

Update your events

Sinovac Launches Phase 3 Trial for COVID-19 Vaccine in Indonesia, Reports Phase 2 Details

Lead Product(s): CoronaVac

Therapeutic Area: Infections and Infectious Diseases Product Name: CoronaVac

Highest Development Status: Phase III Product Type: Vaccine

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable August 11, 2020

Details:

The candidate, known as CoronaVac, is among a few potential vaccines that have entered late-stage trials for a large-scale study to gather proof of efficacy for regulatory approval.

Sinopharm

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CHINA China

Post An Enquiry

Virtual Booth

BE PHARMA 2020

Participation Not Confirmed

Update your events

China's Sinopharm Starts Phase III Trial of COVID-19 Vaccine in Bahrain

Lead Product(s): COVID-19 vaccine

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Phase III Product Type: Vaccine

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable August 10, 2020

Details:

Sinopharm has begun Phase III clinical trials of a COVID-19 vaccine in Bahrain, after launching similar trials in the United Arab Emirates last month.

CanSino Biologics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CHINA China

Post An Enquiry

Virtual Booth

BE PHARMA 2020

Participation Not Confirmed

Update your events

CanSino to Start Phase III Trial of COVID-19 Vaccine in Saudi

Lead Product(s): Ad5-nCoV

Therapeutic Area: Infections and Infectious Diseases Product Name: Ad5-nCoV

Highest Development Status: Phase III Product Type: Vaccine

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable August 09, 2020

Details:

CanSino’s vaccine, co-developed with China’s military research unit, appeared to be safe and induced immune responses in most subjects.

Sinopharm

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CHINA China

Post An Enquiry

Virtual Booth

BE PHARMA 2020

Participation Not Confirmed

Update your events

China's Sinopharm to Test Potential COVID-19 Vaccine in Brazil

Lead Product(s): Inactivated Covid-19 vaccine

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Phase III Product Type: Vaccine

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable July 30, 2020

Details:

Sinopharm and Parana state have agreed to launch the fourth major COVID-19 vaccine trial in Brazil and will seek regulatory approval in the next two weeks, the Brazilian partners said on Wednesday.

Sinopharm

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CHINA China

Post An Enquiry

Virtual Booth

BE PHARMA 2020

Participation Not Confirmed

Update your events

World’s First Phase III Clinical Trial of COVID-19 Inactivated Vaccine Begins in UAE

Lead Product(s): Inactivated Covid-19 vaccine

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Phase III Product Type: Vaccine

Partner/Sponsor/Collaborator: G42 Healthcare

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable July 17, 2020

Details:

The Chairman of the Department of Health, Abu Dhabi, was the first in the world to commence the trial of a Phase III inactivated vaccine for COVID-19 that is the result of a cooperation partnership between Abu Dhabi based G42 Healthcare and Sinopharm CNBG.

Sinovac Biotech

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CHINA China

Post An Enquiry

Virtual Booth

BE PHARMA 2020

Participation Not Confirmed

Update your events

Brazil’s Regulator Approves Trial of Sinovac’s Covid-19 Vaccine

Lead Product(s): CoronaVac

Therapeutic Area: Infections and Infectious Diseases Product Name: CoronaVac

Highest Development Status: Phase III Product Type: Vaccine

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable July 06, 2020

Details:

The Brazilian National Regulatory Agency, Anvisa, has given approval to a Phase III clinical trial sponsored by Instituto Butantan to test the efficacy and safety of the inactivated Covid-19 vaccine "CoronaVac" developed by Sinovac Life Sciences.

Zai Lab

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CHINA China

Post An Enquiry

Virtual Booth

BE PHARMA 2020

Participation Not Confirmed

Update your events

Zai Lab Doses First Chinese Patient in the Global Phase 3 ATTACK Trial of Sulbactam-Durlobactam

Lead Product(s): Durlobactam,Sulbactam

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 18, 2020

Details:

First Chinese patient dosed in the global ATTACK (Acinetobacter Treatment Trial Against Colistin) Phase 3 registrational trial evaluating the combination of sulbactam and durlobactam (SUL-DUR) for the treatment of carbapenem-resistant Acinetobacter baumannii infections.

Find

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Product Type

Companies

CanSino Biologics

China's Cansino Kicks Off Phase III Vaccine Clinical Trials in Russia

Sinovac Biotech

Sinovac Signs Agreement with Bio Farma Indonesia for COVID-19 Vaccine Cooperation

Sinopharm

Sinopharm Shares Phase 2 Data On Inactivated Covid-19 Vaccine

Sinovac Biotech

Sinovac Launches Phase 3 Trial for COVID-19 Vaccine in Indonesia, Reports Phase 2 Details

Sinopharm

China's Sinopharm Starts Phase III Trial of COVID-19 Vaccine in Bahrain

CanSino Biologics

CanSino to Start Phase III Trial of COVID-19 Vaccine in Saudi

Sinopharm

China's Sinopharm to Test Potential COVID-19 Vaccine in Brazil

Sinopharm

World’s First Phase III Clinical Trial of COVID-19 Inactivated Vaccine Begins in UAE

Sinovac Biotech

Brazil’s Regulator Approves Trial of Sinovac’s Covid-19 Vaccine

Zai Lab

Zai Lab Doses First Chinese Patient in the Global Phase 3 ATTACK Trial of Sulbactam-Durlobactam